In this regard, Cocce and colleagues identified the GPI-anchored membrane protein, LYPD3, as a “druggable” downstream target of FOXA1 and the transcription factor, GRHL2 (Grainyhead Like Transcription Factor 2) in endocrine-resistant breast cancer [173]. This evidence concerns the gene GRHL2 and breast carcinoma.